Nasdaq listing awaits Singapore’s US$1.5 billion AI drug-discovery biotech Nanyang Biologics
Its valuation is driven by a proprietary agentic AI platform and potential first-in-class cancer treatment
We haven't written up this one. The Business Times - Companies & Markets has the full story — the link below goes straight to it.